Nov 10 2021
Year-to-date 2021 revenue increased 68% over prior year period BRANFORD, Conn. , Nov. 10, 2021 /PRNewswire/ --  IsoPlexis Corporation (Nasdaq: ISO), the leader in functional single-cell proteomics, today reported financial results for the quarter ended September 30, 2021 .
Oct 12 2021
BRANFORD, Conn. , Oct. 12, 2021 /PRNewswire/ -- IsoPlexis Corporation (" IsoPlexis "), a leader in functional single-cell proteomics, today announced the closing of its initial public offering of 8,333,000 shares of common stock at a public offering price of $15.00 per share.
Oct 07 2021
BRANFORD, Conn. , Oct. 7, 2021 /PRNewswire/ -- IsoPlexis Corporation (" IsoPlexis "), a leader in functional single-cell proteomics, today announced the pricing of its initial public offering of 8,333,000 shares of common stock at a public offering price of $15.00 per share.
Sep 22 2021
BRANFORD, Conn., Sept. 22, 2021 /PRNewswire/ -- IsoPlexis, a leader in functional single-cell proteomics, today announced the appointment of Dr. Jason Myers to its Board of Directors. Dr. Myers joins IsoPlexis' Board of Directors with a wealth of experience in genomics, product development, and
Displaying 1 - 10 of 19